CLINICAL PHARMACOLOGY BLA REVIEW Division of Hematology Office of Blood Review - Blood product - Document - PDFSEARCH.IO

First Page		Document Content
Haemophilia Orders of magnitude		CLINICAL PHARMACOLOGY BLA REVIEW Division of Hematology Office of Blood Review & Research BLA: [removed]Product: BAX326 (RIXUBIS; Recombinant Factor IX) Indication: severe or moderately severe hemophilia B Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 360,88 KB Share Document on Facebook